32 Einträge | 1, 2 › » |
Seite 1 / 2
![]() |
Reply to Rare Versus Artifactual EGFR Mutations. |
Lohinai Z, Ostoros G, Moldvay J, Dome B, Hegedus B |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Jul 23. doi: 10.1097/JTO.0000000000000591. pii: 01243894-201508000-00028 |
PMID: 26200290 |
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. |
Lohinai Z, Hoda MA, Fabian K, Ostoros G, Raso E, Barbai T, Timar J, Kovalszky I, Cserepes M, Rozsas A, Laszlo V, Grusch M, Berger W, Klepetko W, Moldvay J, Dome B, Hegedus B |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Apr 22. doi: 10.1097/JTO.0000000000000492 |
PMID: 25664625 |
Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. |
Cserepes M, Ostoros G, Lohinai Z, Raso E, Barbai T, Timar J, Rozsas A, Moldvay J, Kovalszky I, Fabian K, Gyulai M, Ghanim B, Laszlo V, Klikovits T, Hoda MA, Grusch M, Berger W, Klepetko W, Hegedus B, Dome B |
European journal of cancer (Oxford, England : 1990). 2014 Apr 22. pii: S0959-8049(14)00565-6. doi: 10.1016/j.ejca.2014.04.001 |
PMID: 24768329 |
From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC). |
Lohinai Z, Dome P, Szilagyi Z, Ostoros G, Moldvay J, Hegedus B, Dome B, Weiss GJ |
PloS one. 2016 Jan 6. doi: 10.1371/journal.pone.0144797. pii: PONE-D-15-31766. pmc: PMC4703211 |
PMID: 26735301 |
Claudin-1 Protein Expression Is a Good Prognostic Factor in Non-Small Cell Lung Cancer, but only in Squamous Cell Carcinoma Cases. |
Moldvay J, Fábián K, Jäckel M, Németh Z, Bogos K, Furák J, Tiszlavicz L, Fillinger J, Döme B, Schaff Z |
Pathology oncology research : POR. 2016 Sep 29. doi: 10.1007/s12253-016-0115-0. pii: 10.1007/s12253-016-0115-0 |
PMID: 27687058 |
KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. |
Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, Fabian K, Kovalszky I, Kenessey I, Aigner C, Renyi-Vamos F, Klepetko W, Dome B, Hegedus B |
Scientific reports. 2017 Jan 4. pii: srep39721. doi: 10.1038/srep39721 |
PMID: 28051122 |
Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. |
Téglási V, Reiniger L, Fábián K, Pipek O, Csala I, Bagó AG, Várallyai P, Vízkeleti L, Rojkó L, Tímár J, Döme B, Szállási Z, Swanton C, Moldvay J |
Neuro-oncology. 2017 Feb 13. pii: 2992975. doi: 10.1093/neuonc/now309 |
PMID: 28201746 |
Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis. |
Fábián K, Puskás R, Kakuk T, Prés L, Fejes D, Szegedi Z, Rojkó L, Szállási Z, Döme B, Pipek O, Moldvay J |
Basic & clinical pharmacology & toxicology. 2017 Jul 21. doi: 10.1111/bcpt.12854 |
PMID: 28730730 |
Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis. |
Fábián K, Puskás R, Kakuk T, Prés L, Fejes D, Szegedi Z, Rojkó L, Szállási Z, Döme B, Pipek O, Moldvay J |
Basic & clinical pharmacology & toxicology. 2017 Aug 21. doi: 10.1111/bcpt.12876 |
PMID: 28834230 |
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. |
Rojkó L, Reiniger L, Téglási V, Fábián K, Pipek O, Vágvölgyi A, Agócs L, Fillinger J, Kajdácsi Z, Tímár J, Döme B, Szállási Z, Moldvay J |
Journal of cancer research and clinical oncology. 2018 Apr 19. doi: 10.1007/s00432-018-2642-4. pii: 10.1007/s00432-018-2642-4 |
PMID: 29675791 |
Afatinib restrains K-RAS-driven lung tumorigenesis. |
Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E |
Science translational medicine. pii: 10/446/eaao2301. doi: 10.1126/scitranslmed.aao2301 |
PMID: 29925635 |
Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries. |
Rich A, Baldwin D, Alfageme I, Beckett P, Berghmans T, Brincat S, Burghuber O, Corlateanu A, Cufer T, Damhuis R, Danila E, Domagala-Kulawik J, Elia S, Gaga M, Goksel T, Grigoriu B, Hillerdal G, Huber RM, Jakobsen E, Jonsson S, Jovanovic D, Kavcova E, Konsoulova A, Laisaar T, Makitaro R, Mehic B, Milroy R, Moldvay J, Morgan R, Nanushi M, Paesmans M, Putora PM, Samarzija M, Scherpereel A, Schlesser M, Sculier JP, Skrickova J, Sotto-Mayor R, Strand TE, Van Schil P, Blum TG |
BMC cancer. 2018 Nov 20. doi: 10.1186/s12885-018-5009-y. pii: 10.1186/s12885-018-5009-y |
PMID: 30458807 |
New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study. |
Klikovits T, Lohinai Z, Fábián K, Gyulai M, Szilasi M, Varga J, Baranya E, Pipek O, Csabai I, Szállási Z, Tímár J, Hoda MA, Laszlo V, Hegedűs B, Renyi-Vamos F, Klepetko W, Ostoros G, Döme B, Moldvay J |
Lung cancer (Amsterdam, Netherlands). 2018 Nov 5. pii: S0169-5002(18)30631-7. doi: 10.1016/j.lungcan.2018.11.004 |
PMID: 30527178 |
Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma. |
Reiniger L, Téglási V, Pipek O, Rojkó L, Glasz T, Vágvölgyi A, Kovalszky I, Gyulai M, Lohinai Z, Rásó E, Tímár J, Döme B, Szállási Z, Moldvay J |
Acta oncologica (Stockholm, Sweden). 2019 Apr 19. doi: 10.1080/0284186X.2019.1598575 |
PMID: 31002007 |
PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis. |
Téglási V, Pipek O, Lózsa R, Berta K, Szüts D, Harkó T, Vadász P, Rojkó L, Döme B, Bagó AG, Tímár J, Moldvay J, Szállási Z, Reiniger L |
Clinical lung cancer. 2019 May 15. pii: S1525-7304(19)30112-3. doi: 10.1016/j.cllc.2019.05.008 |
PMID: 31178388 |
Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. |
Lohinai Z, Bonanno L, Aksarin A, Pavan A, Megyesfalvi Z, Santa B, Hollosi V, Hegedus B, Moldvay J, Conte P, Ter-Ovanesov M, Bilan E, Dome B, Weiss GJ |
PeerJ. 2019 Jul 29. doi: 10.7717/peerj.7232. pii: 7232. pmc: PMC6673426 |
PMID: 31392087 |
JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression. |
Mohrherr J, Haber M, Breitenecker K, Aigner P, Moritsch S, Voronin V, Eferl R, Moriggl R, Stoiber D, Győrffy B, Brcic L, László V, Döme B, Moldvay J, Dezső K, Bilban M, Popper H, Moll HP, Casanova E |
International journal of cancer. 2019 Aug 12. doi: 10.1002/ijc.32624 |
PMID: 31407334 |
A clonal expression biomarker associates with lung cancer mortality. |
Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, Boeing S, Krzystanek M, Djureinovic D, La Fleur L, Greco M, Döme B, Fillinger J, Brunnström H, Wu Y, Moore DA, Skrzypski M, Abbosh C, Litchfield K, Al Bakir M, Watkins TBK, Veeriah S, Wilson GA, Jamal-Hanjani M, Moldvay J, Botling J, Chinnaiyan AM, Micke P, Hackshaw A, Bartek J, Csabai I, Szallasi Z, Herrero J, McGranahan N, Swanton C |
Nature medicine. 2019 Oct 7. doi: 10.1038/s41591-019-0595-z. pii: 10.1038/s41591-019-0595-z |
PMID: 31591602 |
KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy. |
Ghimessy AK, Gellert A, Schlegl E, Hegedus B, Raso E, Barbai T, Timar J, Ostoros G, Megyesfalvi Z, Gieszer B, Moldvay J, Renyi-Vamos F, Lohinai Z, Hoda MA, Klikovits T, Klepetko W, Laszlo V, Dome B |
Cancers. 2019 Oct 9. pii: cancers11101514. doi: 10.3390/cancers11101514 |
PMID: 31600989 |
Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases. |
Lohinai Z, Megyesfalvi Z, Suda K, Harko T, Ren S, Moldvay J, Laszlo V, Rivard C, Dome B, Hirsch FR |
Translational lung cancer research. doi: 10.21037/tlcr.2019.11.30. pii: tlcr-08-06-938. pmc: PMC6976364 |
PMID: 32010572 |
32 Einträge | 1, 2 › » |
Seite 1 / 2
![]() |